Pfizer has sold its entire remaining 7.3% stake in Haleon, the consumer healthcare firm, for approximately 2.5 billion pounds, equivalent to $3.24 billion. The shares were sold to institutional investors and Haleon itself at 385 pence per share.
This transaction marks the complete divestiture of Pfizer's interest in Haleon, following previous share sales. The move aligns with Pfizer's strategic objective to streamline its portfolio and concentrate on its core biopharmaceutical business.
The sale generates substantial capital for Pfizer, enhancing its financial flexibility. These funds can be deployed for strategic investments in its pipeline, acquisitions, or further debt reduction, supporting the company's long-term growth initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.